Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirasemtiv SCHEMBL27969614 | 0.87 | CYP1A2 (1.00) | CYP1A2MTORFYNPDE4B | |
| Tirasemtiv SCHEMBL976988 | 0.87 | CYP1A2 (1.00) | CYP1A2MTORFYNPDE4B | |
| SCHEMBL977863 | 0.86 | CYP1A2 (0.75) | CYP1A2MTORFYN | |
| SCHEMBL978074 | 0.82 | CYP1A2 (0.70) | CYP1A2MTORFYNGRIN1GRIN2B | |
| SCHEMBL977476 | 0.81 | CYP1A2 (0.67) | CYP1A2MTORFYNGRIN1GRIN2B | |
| SCHEMBL977805 | 0.80 | CYP1A2 (0.66) | CYP1A2MTORMAPK1FYNGRIN1 | |
| SCHEMBL978051 | 0.80 | CYP1A2 (0.66) | CYP1A2MTORFYNGRIN1GRIN2B | |
| SCHEMBL976625 | 0.80 | CYP1A2 (0.66) | CYP1A2MTORFYNGRIN1GRIN2B | |
| SCHEMBL975997 | 0.79 | CYP1A2 (0.65) | CYP1A2MTORFYN | |
| SCHEMBL975769 | 0.78 | CYP1A2 (0.64) | CYP1A2MTORFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| CN-111840294-A | Method for improving resistance to skeletal muscle fatigue | 赛特凯恩蒂克公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2995619-B1 | CERTAIN CHEMICAL ENTITIES COMPRISING IMIDAZOPYRIMIDINES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885MTOR 607/4885PGR 3446/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | CYP1A2 4687/4885MTOR 4448/4885PGR 4829/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885MTOR 607/4885PGR 3446/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | CYP1A2 20/4885MTOR 3297/4885PGR 924/4885 |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | CYP1A2 4298/4885MTOR 3118/4885PGR 4595/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885MTOR 607/4885PGR 3446/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | CYP1A2 3227/4885MTOR 2781/4885PGR 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.